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Abstract
Background: Regulatory risk communications are an important method for disseminating drug safety information, but their
impact varies. Two significant UK risk communications about antipsychotic use in older people with dementia were issued
in 2004 and 2009. These varied considerably in their content and dissemination, allowing examination of their differential
impact.
Methods: Segmented regression time-series analysis 2001–2011 for people aged $65 years with dementia in 87 Scottish
general practices, examining the impact of two pre-specified risk communications in 2004 and 2009 on antipsychotic and
other psychotropic prescribing.
Results: The percentage of people with dementia prescribed an antipsychotic was 15.9% in quarter 1 2001 and was rising
by an estimated 0.6%/quarter before the 2004 risk communication. The 2004 risk communication was sent directly to all
prescribers, and specifically recommended review of all patients prescribed relevant drugs. It was associated with an
immediate absolute reduction in antipsychotic prescribing of 5.9% (95% CI 26.6 to 25.2) and a change to a stable level of
prescribing subsequently. The 2009 risk communication was disseminated in a limited circulation bulletin, and only
specifically recommended avoiding initiation if possible. There was no immediate associated impact, but it was associated
with a significant decline in prescribing subsequently which appeared driven by a decline in initiation, with the percentage
prescribed an antipsychotic falling from 18.4% in Q1 2009 to 13.5% in Q1 2011. There was no widespread substitution of
antipsychotics with other psychotropic drugs.
Conclusions: The two risk communications were associated with reductions in antipsychotic use, in ways which were
compatible with marked differences in their content and dissemination. Further research is needed to ensure that the
content and dissemination of regulatory risk communications is optimal, and to track their impact on intended and
unintended outcomes. Although rates are falling, antipsychotic prescribing in dementia in Scotland remains unacceptably
high.
Citation: Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR (2013) Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People
with Dementia in Scotland: Segmented Regression Time Series Analysis 2001–2011. PLoS ONE 8(7): e68976. doi:10.1371/journal.pone.0068976
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received April 2, 2013; Accepted June 11, 2013; Published July 17, 2013
Copyright:  2013 Guthrie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Scottish Government Mental Health Division, and DM is supported by a Scottish Government Chief Scientist Office Clinical
Academic Fellowship (CAF/11/07). The authors had full and sole access to the data. The funder had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: BG, DM, SC and CM declare they have no competing interests.
In the previous five years, ER has served on advisory boards for Lundbeck and Nutricia who might have an interest in the submitted work, but had no role in this
study whatsoever. There are no other potential competing interests to report. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing
data and materials.
* E-mail: b.guthrie@dundee.ac.uk
Introduction
Regulatory risk communications of various kinds are an
important way of ensuring that prescribers are informed about
new evidence of drug benefit and harm that emerges post-
licencing. The impact and effectiveness of regulatory risk
communications is highly variable though, with a systematic
review of studies of the impact of US Food and Drugs
Administration (FDA) risk communications finding that impact
appeared to vary with the nature and specificity of the warning [1].
For example, recommendations to monitor treatment more closely
had little impact whereas recommendations to avoid use in
particular patient subgroups often did lead to reductions in use,
especially if risk communications stated specific actions prescribers
should take [1]. Although risk communications can therefore
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change prescribing, effects are variable and it is unclear how best
to design or disseminate them [1,2].
Antipsychotic drug use in older people with dementia has been
the subject of several regulatory risk communications since 2002
[3–6]. Antipsychotic drugs are frequently prescribed with the aim
of reducing behavioural and psychological symptoms of dementia
(BPSD) in older people. In Scotland in 2007, 17.7% of people with
a diagnosis of dementia were prescribed an antipsychotic [7],
compared to approximately 12% in 2005–2007 in one US study
[8]. Despite this high rate of use, antipsychotics have only limited
benefit in treating BPSD in older people with dementia and carry
significant risk of harm [9–12]. In 2009, antipsychotics were
estimated to cause approximately 1800 deaths and 1620 cerebro-
vascular events in people with dementia in the UK annually [13].
However, clinical trial evidence in nursing home patients with
dementia indicates that chronically prescribed antipsychotic drugs
can be safely discontinued in most patients, with longer term
follow-up suggesting a significant reduction in mortality [14] [15].
In the UK two main risk communications have been
disseminated by the Medicines and Healthcare products Regula-
tory Agency (MHRA). The first was issued in March 2004, and
highlighted newly discovered risks of stroke and death due to
risperidone and olanzapine. It was directly and urgently dissem-
inated to all prescribers, and contained explicit and clear guidance
on how prescribers should respond (table 1) [3]. The second was
issued in March 2009 and emphasised that these risks were
associated with all antipsychotics. It was primarily disseminated in
a limited circulation bulletin, with no explicit guidance on how
prescribers should respond beyond being cautious in initiation
(table 1), [16] although there were a number of other related
guidance issued at around the same time. [5,13,17,18] The aim of
this study was to assess the impact of the 2004 and 2009 risk
communications on antipsychotic and other psychotropic drug
prescribing to older people with dementia in Scotland.
Materials and Methods
Ethics Statement
National Health Service Research Ethics Committee (NHS
REC) review was not required because all data management and
analysis only used anonymised data and was carried out consistent
with the PCCIU standard operating procedures which have
themselves been approved by the NHS Grampian Research Ethics
Committee. All analysis was carried out using PASW Statistics v18
(IBM Software 2009).
Population Studied
The population studied was patients aged 65 and over
permanently registered with 87 Scottish general practices which
contributed data for the entire period to a dataset held by the
Primary Care Clinical Information Unit (PCCIU), University of
Aberdeen. All participating practices consented to research use of
anonymised data at the time of data extraction in Spring 2011.
Data were extracted for all patients with a diagnosis of dementia at
any point between 1st January 2001 and 31st March 2011.
Dementia was defined either as the presence of a Quality and
Outcomes Framework (QOF) defined dementia Read Code (used
to define disease registers under the UK National Health Service
contract for GPs) [19], an NHS Scotland Information Services
Division defined dementia Read Code [20], or if the patient had
ever having been prescribed an anticholinesterase inhibitor drug
(defined as drugs listed in British National Formulary [BNF]
section 4.11). Since antipsychotics are indicated in some older
people with dementia and psychosis, people with QOF-defined
‘severe and enduring mental illness’ (predominately schizophrenia
and related psychoses or severe bipolar disorder) were excluded
from analysis. A quarterly time-series analysis was created, where
individuals were included in analysis for each quarter if they were
aged 65 years and over and had a dementia diagnosis at the
beginning of the quarter.
Table 1. 2004 and 2009 risk communications concerning antipsychotic use in older people with dementia.
Risk
communication
Statement of risk
(bold as in original text) Advice on action (bold as in original text)
March 2004 risk
communication
(sent in a letter to
all healthcare
professionals
marked ‘‘Urgent
message’’) [3]
‘‘The CSM* has advised that there is
clear evidence of an increased risk of
stroke in elderly patients with
dementia who are treated with
risperidone or olanzapine. The
magnitude of this risk is sufficient to
outweigh likely benefits in the
treatment of behavioural disturbances
associated with dementia and is a
cause for concern in any patient with a
high baseline risk of stroke.’’
‘‘Prescribing advice: CSM has advised that risperidone or olanzapine should not
be used for the treatment of behavioural symptoms of dementia. Use of
risperidone for the management of acute psychotic conditions in elderly patients
who also have dementia should be limited to short-term and should be under
specialist advice (olanzapine is not licensed for management of acute psychoses).
Prescribers should consider carefully the risk of cerebrovascular events before
treating any patient with a previous history of stroke or transient ischaemic
attack. Consideration should also be given to other risk factors for
cerebrovascular disease including hypertension, diabetes, current smoking and
atrial fibrillation. Although there is presently insufficient evidence to include other
antipsychotics in these recommendations, prescribers should bear in mind that a risk of stroke
cannot be excluded, pending the availability of further evidence. Studies to investigate this
are being initiated. Patients with dementia who are currently treated with an atypical
antipsychotic drug should have their treatment reviewed. Many patients with
dementia who are disturbed may be managed without medicines. Treatment guidelines are
available at websites listed below.’’
March 2009 risk
communication in
Drug Safety
Update (limited
circulation
bulletin) [16]
‘‘Advice for healthcare professionals:
There is a clear increased risk of
stroke and a small increased risk of
death when antipsychotics (typical or
atypical) are used in elderly people
with dementia.’’
‘‘The balance of risks and benefits associated with risperidone treatment should be carefully
assessed for every patient, taking into consideration the known increased mortality rate
associated with antipsychotic treatment in the elderly. Prescribers should carefully consider
the risk of cerebrovascular events before treating with risperidone any patient who has a
previous history of stroke or transient ischaemic attack. Consideration should also be given to
other risk factors for cerebrovascular disease including hypertension, diabetes, smoking, and
atrial fibrillation.’’
*CSM=Committee for Safety of Medicines.
doi:10.1371/journal.pone.0068976.t001
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Outcomes
In each quarter, eligible patients were defined as being
prescribed a particular drug class if they received one or more
relevant prescriptions in that quarter. The drug classes studied
were oral antipsychotics (drugs in BNF chapter 4.2.1), hypnotics
(BNF 4.1.1), anxiolytics (BNF 4.1.2) and antidepressants (BNF
4.1.3), and the outcomes measured were the receipt of one or more
relevant prescriptions for each drug class in any particular quarter.
Two additional outcomes were defined. Antipsychotic initiation
was defined as a patient receiving an antipsychotic in a particular
quarter when there had been no antipsychotic prescription in the 6
months before the date of issue. Antipsychotic discontinuation was
defined as a patient who had received an antipsychotic in the
previous quarter but not in the current quarter.
Statistical Methods
Time series for the specified outcomes were plotted and the
impact of the two pre-specified regulatory risk communications
examined in a single segmented regression analysis model, which is
a form of interrupted time series analysis commonly used to
evaluate policy interventions [21]. This method estimates three
key parameters for each intervention: a) the slope or trend in
prescribing before the intervention; b) the change in the level of
prescribing immediately following the intervention; and c) the
change in trend from the pre-intervention trend.
The dates chosen for the intervention were pre-specified as the
date of dissemination of the two regulatory risk communications,
which in both cases was at the end of the first quarter of the
relevant year. Quarter 2 in 2004 and 2009 were therefore defined
as the first post-risk communication time-point. The minimum
number of people with dementia being measured in any time point
was 1912, and the analysis was weighted for the number of
patients with dementia included in each time point. The presence
of serial autocorrelation was tested for in each model using the
Durbin-Watson statistic and the Breusch-Godfrey test, but was not
found to be significant in any model. Where appropriate, seasonal
effects were accounted for by fitting fixed effects for ‘quarter’ as an
independent variable using Aikake’s Information Criteria to select
the best fitting model. Only main effects are presented in the
paper.
Results
Between 2001 and 2011, the total number of patients aged 65
years and over rose from 76,506 to 82,497 with the largest relative
increases in the over-85s. The number of patients recorded as
having dementia increased from 1912 (prevalence 2.5% of over 65
year olds, 95% CI 2.4–2.6) in quarter 1 2001 to 3478 (4.2%, 95%
CI 4.1–4.4) in quarter 1 2011, which was only partially explained
by the rise in the total number of people aged 65 and over, and the
very elderly in particular (the dementia prevalence in quarter 1
2011 directly standardised to the quarter 1 2001 population
structure was 3.8% (95% CI 3.7–3.9)). There were no changes in
the rising trend in the prevalence of dementia around the times of
the risk communications in 2004 and 2009. Across the entire
period, approximately 1% of over-65s were excluded because they
had a ‘severe and enduring mental illness’ diagnosis. The majority
of people with dementia were women across the whole time period
(75.8% in quarter 1 2001 and 68.9% in quarter 1 2011).
Figure 1 shows time trends in the percentage of patients with
recorded dementia prescribed any antipsychotic, with segmented
regression analysis results for any antipsychotic prescription in
table 2. In the segmented regression model, for all antipsychotics,
there was a significantly rising trend in antipsychotic prescribing
before the 2004 risk communication of 0.61% (95% CI 0.53 to
0.68) absolute increase per quarter from a model estimated
baseline of 13.9% (table 2). The 2004 risk communication was
associated with a large immediate absolute fall in antipsychotic
prescribing of 25.94% (95% CI 26.64 to 25.23), with a
downward change in trend of 20.54% per quarter (95% CI
20.63 to 20.45) afterwards. The overall effect was therefore of a
large immediate drop in prescribing, with a change from a steadily
rising trend (an additional 0.61% of people with dementia are
prescribed an antipsychotic every quarter) to a flat one (0.61%
minus 0.54%=0.07% increase per quarter). In contrast, the 2009
risk communication was not associated with any immediate
reduction in total antipsychotic prescribing, but there was a
statistically significant change in trend of 20.51% (95% CI 20.64
to 20.37) per quarter in absolute rates of prescribing, equating to
a shift from a flat to a falling trend.
Figure 1 additionally shows the absolute number of people with
recorded dementia prescribed an antipsychotic. Although the
immediate changes and changes in trend are broadly mirrored in
the absolute numbers prescribed, there were more people with
recorded dementia prescribed an antipsychotic in 2011 than in
2001, reflecting that recorded prevalence had increased. Time
trends for individual drugs show that prescribing of the two drugs
specifically warned against (risperidone and olanzapine) fell rapidly
in the quarter immediately after the 2004 risk communication,
with partial replacement with other antipsychotics, predominately
haloperidol initially (figure 2).
The 2004 risk communication was associated with a transient
decrease of 20.74% (21.34 to 20.14) in antipsychotic initiation,
without any statistically significant change in trend. In contrast,
the 2009 risk communication was not associated with any
immediate change, but there was a downward change in trend
of 20.17% (95% CI 20.28 to 20.06) (table 2, figure 3). For
antipsychotic discontinuation, there was a statistically significant
transient increase immediately after the 2004 risk communication,
but no subsequent change in trend, and no significant change of
any kind following the 2009 risk communication (table 2, figure 4).
Time trends in prescribing of other psychotropic drugs are
shown in figure 4, with segmented regression results in table 2.
The 2004 risk communication was associated with transient
absolute increases in hypnotic, anxiolytic, and antidepressant
prescribing of 1.37% (95% CI 0.75 to 2.00), 1.32% (0.76 to 1.89)
and 1.78% (0.20 to 3.36) among patients age 65 and over with
dementia respectively. Hypnotic prescribing was static before
2004, with anxiolytic and antidepressant prescribing both signif-
icantly increasing, but there was no significant change in trends in
any of the three drug classes in association with the 2004 risk
communication. The 2009 risk communication was not signifi-
cantly associated with any immediate change in prescribing of any
of the three drug classes, but was associated with significant
decreases in trend of 20.25% per quarter for hypnotics, 20.37%
per quarter for anxiolytics and 20.69% per quarter for
antidepressants.
Discussion
Summary of Findings
Although causality cannot be definitively ascribed, both the
2004 and 2009 MHRA risk communications were associated with
statistically significant changes in antipsychotic prescribing.
However the magnitude and patterns of change associated with
each risk communication differed significantly. The 2004 risk
communication was associated with an immediate large fall in the
level of antipsychotic prescribing and a moderate change in the
Risk Communications and Antipsychotic Prescribing
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Figure 1. Prescribing of all oral antipsychotics in people aged $65 years with dementia.
doi:10.1371/journal.pone.0068976.g001
Table 2. Segmented regression analysis of changes in antipsychotic and other psychotropic prescription in relation to the 2004
and 2009 risk communications.
Baseline quarter
1 2001 (intercept)
% (95% CI)
Trend before
2004 risk
communication
% (95% CI)
Change in level
after 2004 risk
communication
% (95% CI)
Change in trend
after 2004 risk
communication*
% (95% CI)
Change in level
after 2009 risk
communication
% (95% CI)
Change in trend
after 2009 risk
communication*
% (95% CI)
Oral antipsychotic
prescribed
13.89
(13.24 to 14.53)
0.61
(0.53 to 0.68)b
25.94
(26.64 to 25.23)b
0.54
(20.63 to 20.45)b
0.06
(20.72 to 0.84)
20.51
(20.64 to 20.37)b
Oral antipsychotic
initiated
3.18
(2.47 to 3.89)
0.04
(20.04 to 0.13)
20.74
(21.34 to 20.14)a
0.03
(20.11 to 0.06)
20.10
(20.73 to 0.53)
20.17
(20.28 to 20.06)a
Oral antipsychotic
discontinued
2.75
(1.92 to 3.58)
20.06
(20.16 to 0.03)
1.04
(0.24 to 1.84)a
0.01
(20.12 to 0.10)
0.03
(20.82 to 0.88)
0.08
(20.06 to 0.23)
Hypnotic prescribed 8.63
(8.06 to 9.20)
0.02
(20.05 to 0.09)
1.37
(0.75 to 2.00)b
0.08
(20.15 to 0.002)
0.51
(20.18 to 1.20)
20.25
(20.37 to 20.13)b
Anxiolytic prescribed 2.76
(2.24 to 3.27)
0.14
(0.08 to 0.21)b
1.32
(0.76 to 1.89)b
0.02
(0.09 to 0.05)
0.45
(20.17 to 1.07)
20.37
(20.47 to 20.26)b
Antidepressant prescribed 17.19
(15.74 to 18.63)
0.71
(0.53 to 0.88)b
1.78
(0.20 to 3.36)a
0.18
(20.37 to 0.02)
0.47
(21.28 to 2.21)
20.69
(20.99 to 20.38)b
ap,0.05;
bp,0.001.
*Value is the change in trend not the subsequent trend, and interpretation of the model should be in conjunction with examining the time trend graphs. For example,
for oral antipsychotics the trend before the 2004 intervention is a rising one, with an increase of 0.61% per quarter. There is a statistically significant downward change
in trend of 0.54% per quarter, so the post-2004 risk communication estimated trend is an increase of 0.07% per quarter. There is a further statistically significant
downward change in trend of 0.51% per quarter after the 2009 risk communication, so the post-2009 risk communication estimated trend is a decrease of 0.44% per
quarter.
doi:10.1371/journal.pone.0068976.t002
Risk Communications and Antipsychotic Prescribing
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trend which was rising before it and flat after it. There was an
associated decrease in both antipsychotic initiation and increase in
antipsychotic discontinuation. In contrast, the 2009 risk commu-
nication was not associated with any immediate change in
antipsychotic prescribing, but was associated with a change in
trend from flat to falling of a similar magnitude to 2004. This was
associated with a decline in antipsychotic initiation, with no
evidence of any change in antipsychotic discontinuation. There
was no evidence of associated significant substitution with other
psychotropic drugs after either risk communication, and the 2009
risk communication was associated with significant downward
changes in the trend for all three drug classes. While there did not
appear to be immediate substitution, it is notable that antidepres-
sant prescribing doubled over the 10 years examined (a greater
increase than in general population antidepressant use over the
period 1997–2010 [22]), although this trend flattened after 2009.
Strengths and Limitations of the Analysis
The study used routine healthcare data which allowed the
analysis of a long time series in a large dataset, but suffers the
limitations that all such studies do in terms of the data potentially
being incomplete because it was collected for another purpose. A
particular issue is that dementia is known to be under-recorded
historically (although Scottish recording is reasonably close to
epidemiological predictions) [23]. The quarter 1 2011 dementia
prevalence in this study was 4.2% in people aged 65 and over,
compared to estimates of 6.6% and 6.4% from the largest UK
study and an Europe-wide meta-analysis respectively [24].
However, the age-standardised prevalence of dementia in people
aged 65 years and over increased from 2.5% in quarter 1 2001 to
3.8% in quarter 1 2011, and as figure 1 shows there were more
people with a recorded diagnosis of dementia being prescribed an
oral antipsychotic in 2011 than in 2001. Similar changes in
recorded prevalence of dementia were seen in the Veteran’s
Administration study by Kales et al [8], and there were no step
changes in prevalence around the time of the risk communications
that could explain the findings, particularly with regards the
immediate impact of the 2004 risk communication. A second issue
is that the study does not have data on reasons for antipsychotic
prescribing, and so cannot examine the perceived indication for
antipsychotic initiation, continuation or stopping. Although the
data is consistent with the risk communications leading to a
change in prescribing practice and the study design is as rigorous a
method as can be used in the absence of randomisation [21], it is
not possible to definitely ascribe causation to the observed
association.
Comparison with Other Studies
Three North American studies have examined the impact of
regulatory risk communications on antipsychotic prescribing
[8,25,26]. In Canada, three regulatory risk communications in
the period 2002–2005 reduced the rate of growth of antipsychotic
prescribing in people with dementia and caused some shift from
risperidone and olanzapine to quetiapine [25], but total antipsy-
chotic prescribing in older people continued to increase [27]. Two
US studies of the impact of the 2005 FDA risk communications
showed falls in antipsychotic use in older people with dementia
[8,26], but there was little immediate impact on the scale observed
Figure 2. Prescribing of selected oral antipsychotics in people aged $65 years with dementia.
doi:10.1371/journal.pone.0068976.g002
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in the study reported here in association with the 2004 risk
communication. To our knowledge, there are no published studies
of subsequent regulatory risk communications in this field. Kales
et al’s study in the Veterans’ Administration population also
examined the use of other psychotropics, finding no change in
hypnotic, anxiolytic or antidepressant use [8]. In contrast, our
study shows that antidepressant prescribing rose considerably over
the whole period. Although we found some evidence of transient
substitution of other psychotropics for antipsychotics in 2004, the
more striking finding was that prescribing of hypnotics, anxiolytics
and antidepressants either flattened off or declined after the 2009
risk communication. This highlights that regulatory risk commu-
nications may have unexpected effects beyond the prescribing
targeted, and evaluation should ideally seek to examine unintend-
ed as well as intended consequences [28,29].
The NHS England national prescribing audit published in July
2012 showed a reduction in the proportion of older people with
recorded dementia prescribed an antipsychotic from 17.0% in
2006 to 6.8% in 2011, [30] compared with the observed reduction
in this study from 16.9% in quarter 1 2006 to 13.5% in quarter 1
2011. In England, the 2009 risk communication was reinforced by
a Department of Health commitment to reduce antipsychotic
prescribing in older people with dementia by two-thirds over two
years [13] [18]. In contrast, there was no such clear policy
response in NHS Scotland. The greater observed fall in
antipsychotic prescribing in England is consistent with there being
an additional impact of the policy response over and above the risk
communication directed at the whole UK. However, it is
important to note that the number of people with recorded
dementia in the English audit more than doubled since 2006,
compared with an ,33% increase in the Scottish data examined
in this analysis over the same period (reflecting Scotland’s better
historical recording of dementia in GP records [23]). Changes in
rates of antipsychotic use over time have to be treated with caution
because of the shifting denominator of ‘recorded dementia’.
Interpretation of the Findings
In an observational design of this nature, it is not possible to
definitively ascribe causality to the statistical associations seen in
segmented regression models of the kind used here. However, the
2004 risk communication was associated with a large change in
prescribing consistent with the nature of the warning disseminated
urgently to all prescribers (table 1). On the background of
previously rising trends in the use of both, risperidone and
olanzapine prescribing more than halved in the quarter following
the risk communication (from 12.5% of older people with
dementia to 5.6% for risperidone, and from 3.3% to 1.5% for
olanzapine), with only partial immediate replacement by other
antipsychotics. Our interpretation is that the 2004 risk commu-
nication prompted widescale review of people with dementia
prescribed antipsychotics, with large changes in prescribing.
Interpretation of the impact of the 2009 risk communication is
more ambiguous. There was no immediate change in antipsy-
chotic prescribing, although we observed a statistically significant
decline in antipsychotic use subsequently. This reduction in
antipsychotic use was associated with a decline in initiation, was
consistent with the 2009 risk communication which only
highlighted caution in initiation as a specific action for prescribers
Figure 3. New antipsychotic prescribing and antipsychotic stopping in people aged $65 years with dementia.
doi:10.1371/journal.pone.0068976.g003
Risk Communications and Antipsychotic Prescribing
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(table 1). However, it is important to note that other publications
at around the same time also highlighted concern about
antipsychotic use in older people with dementia, including the
European Medicines Agency report in December 2008 that
prompted the 2009 risk communication, [5] the English National
Dementia Strategy in February 2009, [17] and the English
Department of Health ‘Time for Action’ report about antipsy-
chotic use in older people with dementia published in November
2009 [13] (although the latter two did not strictly speaking apply in
Scotland, they may still have affected practice). It is therefore
possible that the observed statistically significant association
between the 2009 risk communication and changes in antipsy-
chotic prescribing is spurious. Our interpretation is that the impact
of the 2009 risk communication was small at best, in contrast with
the changes associated with the 2004 risk communication.
Although causality cannot be proven, our interpretation is that
the data is consistent with the two risk communications having an
impact which reflected differences in the nature and dissemination
of the two risk communications. The 2004 risk communication
made very explicit statements of the magnitude of risk, had specific
recommendations to avoid, review and stop named drugs, and was
urgently disseminated directly to all prescribers. In contrast, the
2009 risk communication made a less clear recommendation to be
cautious in initiation, did not explicitly recommend review or
stopping, and was disseminated via a limited circulation routine
bulletin (table 1).
While it is impossible to know what the ‘right’ level of
antipsychotic prescribing in older people with dementia is, it is
notable that large numbers of older people with dementia continue
to be treated with antipsychotics. Such prescribing is often in
response to the need to manage distressing behavioural and
psychological disturbance. Given the lack of highly effective
alternative treatments, the correct level of antipsychotic use in this
population is unlikely to be zero, although it is almost certainly less
than current levels in Scotland [13,31].
Implications of the Findings
This study provides further evidence that risk communications
from regulators do change clinical practice, although it raises
important questions about how such risk communications should
best be designed and disseminated [1]. Although an observational
study cannot definitively ascribe causality, we believe that the 2004
risk communication was associated with a large change in
prescribing, including a large initial impact most likely because it
prompted widescale review of patients already being prescribed
antipsychotics. While the 2009 risk communication was not
associated with any immediate change in prescribing, the rates of
prescribing subsequently fell (although whether this is due to the
risk communication or other publications and policy activity
around the same time cannot be determined in an analysis with
pre-specified interventions to examine). The limited dissemination
of the 2009 risk communication is of particular note. There were
seven other risk communications sent directly to healthcare
professionals in the UK in the first quarter of 2009, relating to
efavirenz, temsirolimus, toremifine, bevacizumab, efalizumab,
recombinant coagulation factor VIII, and fondaparinux [32].
Additionally, there was a large campaign to publicise new advice
about the risks of over the counter preparations for colds and
Figure 4. Hypnotic, anxiolytic and antidepressant prescribing in people aged $65 years with dementia.
doi:10.1371/journal.pone.0068976.g004
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coughs in children [33]. Despite being more urgently and more
widely disseminated, none of these were associated with the scale
of harm of antipsychotics in dementia, which in 2009 were
estimated to kill approximately 1800 people in the UK, and to
additionally cause a further 1620 cerebrovascular events [13]. We
therefore believe that the effectiveness of regulatory risk commu-
nications could be improved by better attention to the content and
method of dissemination of risk communications, tailored to the
level of risk and harm involved. Based on the larger observed
changes in prescribing associated with the 2004 risk communica-
tion, and the smaller observed changes in 2009 despite multiple
policy publications as well as the risk communication, it is also
plausible that a clear and authoritative recommendation to review
patients with dementia prescribed antipsychotics disseminated
directly to prescribers would lead to wide-scale, targeted review
and significant implementation of the guidance to stop antipsy-
chotics wherever possible.
Conclusions
This analysis provides evidence that risk communications from
regulators did reduce antipsychotic prescribing in older people
with dementia, but the observational design means that it is not
possible to definitively ascribe any changes in prescribing with the
warning. However, the evidence for impact is much stronger for
the 2004 than the 2009 risk communication, consistent with the
marked differences in their design and method of dissemination.
Although impact in this kind of real-world intervention is likely to
vary with context, the findings are consistent with previous
research examining the impact of FDA risk communications in
terms of impact varying with the design of the warning, and in
particular of warnings clearly specifying the actions expected of
prescribers having greater impact [1]. There is a need for applied
research to systematically examine why impact varies in order to
understand how better to design and disseminate regulatory risk
communications to maximise effectiveness, and to routinely
monitor the impact of risk communications on both intended
and unintended consequences.
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